PMID- 29493370
OWN - NLM
STAT- MEDLINE
DCOM- 20190109
LR  - 20190109
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
VI  - 11
IP  - 4
DP  - 2018 Apr
TI  - Update on current research into haploidentical hematopoietic stem cell 
      transplantation.
PG  - 273-284
LID - 10.1080/17474086.2018.1447379 [doi]
AB  - Haploidentical stem cell transplantation (Haplo-SCT) is currently a suitable 
      alternative worldwide for patients with hematological diseases, who lack human 
      leukocyte antigen (HLA)-matched siblings or unrelated donors. Areas covered: This 
      review summarizes the advancements in Haplo-SCT in recent years, primarily 
      focusing on the global trends of haploidentical allograft, the comparison of 
      outcomes between Haplo-SCT and other transplantation modalities, strategies for 
      improving clinical outcomes, including donor selection, hematopoietic 
      reconstitution promotion, and graft-versus-host disease, and relapse 
      prevention/management, as well as the expanded indications of Haplo-SCT, such as 
      severe aplastic anemia, myeloma and lymphoma. Expert commentary: Haploidentical 
      allografts, including granulocyte colony-stimulating factor-based protocol and a 
      post-transplant cyclophosphamide-based protocol, have been the mainstream 
      strategy for Haplo-SCT. However, there are many unanswered questions in this 
      field.
FAU - Sun, Yu-Qian
AU  - Sun YQ
AD  - a Peking University People's Hospital , Peking University Institute of Hematology 
      , Beijing , China.
AD  - b Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the 
      Treatment of Hematological Diseases , Beijing , P.R. China.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - a Peking University People's Hospital , Peking University Institute of Hematology 
      , Beijing , China.
AD  - b Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the 
      Treatment of Hematological Diseases , Beijing , P.R. China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AUID- ORCID: 0000-0002-2145-6643
AD  - a Peking University People's Hospital , Peking University Institute of Hematology 
      , Beijing , China.
AD  - b Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the 
      Treatment of Hematological Diseases , Beijing , P.R. China.
AD  - c Peking-Tsinghua Center for Life Sciences , Beijing , China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180306
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Allografts
MH  - *HLA Antigens
MH  - Hematologic Diseases/*therapy
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Histocompatibility Testing/*methods
MH  - Humans
OTO - NOTNLM
OT  - Baltimore protocol
OT  - Beijing protocol
OT  - graft-versus-host disease
OT  - haploidentical stem cell transplantation
OT  - poor graft function
OT  - relapse
OT  - severe aplastic anemia
EDAT- 2018/03/02 06:00
MHDA- 2019/01/10 06:00
CRDT- 2018/03/02 06:00
PHST- 2018/03/02 06:00 [pubmed]
PHST- 2019/01/10 06:00 [medline]
PHST- 2018/03/02 06:00 [entrez]
AID - 10.1080/17474086.2018.1447379 [doi]
PST - ppublish
SO  - Expert Rev Hematol. 2018 Apr;11(4):273-284. doi: 10.1080/17474086.2018.1447379. 
      Epub 2018 Mar 6.